NEW YORK, March 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Stryker Corporation (NYSE: SYK), ArthroCare Corporation (NASDAQ:
ARTC), Novavax, Inc. (NASDAQ: NVAX), The Cooper Companies, Inc.
(NYSE: COO), and Varian Medical Systems, Inc. (NYSE: VAR). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Stryker Corporation Analyst Notes
On March 7, 2014, Stryker
Corporation (Stryker) reported that it has completed the previously
announced acquisition of Pivot Medical Inc. According to Stryker,
as indicated previously on February 19,
2014, the transaction is expected to be neutral to its 2014
earnings per share excluding acquisition, integration-related and
intangible amortization charges. The full analyst notes on Stryker
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03142014/SYK/report.pdf
--
ArthroCare Corporation Analyst
Notes
On March 11, 2014, shares of
ArthroCare Corporation (ArthroCare) increased 0.02% to close at
$48.18. ArthroCare's shares dropped
slightly 0.15% over the previous three trading sessions, while the
Nasdaq Composite Index dipped 1.03% during the same period. The
full analyst notes on ArthroCare Corporation are available to
download free of charge at:
http://www.AnalystsReview.com/03142014/ARTC/report.pdf
--
Novavax, Inc. Analyst Notes
On March 10, 2014, Novavax, Inc.
(Novavax) announced that it has appointed John J. Trizzino as Senior Vice President,
Commercial Operations, effective immediately. According to the
Company, Trizzino will be responsible for developing and
implementing the commercialization strategy in support of the
Company's product candidates, including its RSV F, quadrivalent
seasonal and pandemic influenza vaccine candidates. Prior to his
appointment, Trizzino served as Novavax' Senior Vice President of
International and Government Alliances, beginning in 2009 and its
Senior Vice President of Business Development from 2010 to 2011.
Stan Erck, President and CEO of
Novavax, said, "With our success in product development in the
clinic, and our expectations around future development plans, we
recognize the need to maximize the value of our vaccine candidates
through a fully developed commercialization strategy. John's
knowledge of the vaccine industry, with specific experience in
vaccine commercialization, distribution and reimbursement, provide
us with the insight needed to develop that commercialization
strategy. We are very excited to have John return to the team and
look forward to his contributions to our success." The full
analyst notes on Novavax, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/03142014/NVAX/report.pdf
--
The Cooper Companies, Inc. Analyst
Notes
On March 6, 2014, The Cooper
Companies, Inc. (Cooper) released its Q1 FY 2014 financial results
(period ended January 31, 2014). For
the quarter, Cooper reported a 6.6% YoY rise in net sales of
$405.0 million. Q1 FY 2014 net income
attributable to Cooper's stockholders stood at $71.8 million or $1.47 per diluted share, compared with
$74.7 million or $1.50 per diluted share in Q1 FY 2013. "We are
very pleased to report a strong first quarter. CooperVision
continued to gain share in all geographies and modalities with
silicone hydrogel products showing especially strong growth led by
Biofinity®. CooperSurgical also continued to post solid revenue
growth in fertility. Our businesses continue to perform well and we
remain excited about the future," commented Robert S. Weiss, Cooper's President and CEO. The
full analyst notes on The Cooper Companies, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03142014/COO/report.pdf
--
Varian Medical Systems, Inc. Analyst
Notes
On March 11, 2014, Varian Medical
Systems, Inc. (Varian) reported that Meridian Health of
New Jersey has initiated a program
to deploy TrueBeam™ technology from the Company across its network
of cancer treatment clinics. The Company stated that Meridian plans
to install seven TrueBeam machines at its five sites, together with
Varian's ARIA® data management and Eclipse™ treatment planning
software. The network will be integrated and centrally managed
using Varian's FullScale™ cloud-based oncology IT data hosting
solution. Commenting on the development, Mark J. Krasna, M.D., Corporate Medical Director
for Meridian Cancer Care, said, "These new technologies will
support our multi-disciplinary team of experts us as we continue to
expand our state of the art radiation therapy program at Meridian.
The TrueBeam machines help enhance our radiosurgery capabilities to
patients throughout central and southern New Jersey, offer many patients shorter
treatments, and add arc therapy to the range of treatment options
we currently utilize." The full analyst notes on Varian Medical
Systems, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03142014/VAR/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review